Opinion|Videos|October 14, 2024
Challenges Associated With Dravet Syndrome Treatment
Author(s)M. Scott Perry, MD
Key Takeaways
- Dravet syndrome's genetic basis and seizure variability complicate treatment, necessitating personalized approaches and regular monitoring.
- Escalation therapy requires careful evaluation of drug efficacy, side effects, and patient-specific factors to ensure optimal outcomes.
Scott Perry, MD, discusses how treatment challenges in Dravet syndrome necessitate careful monitoring by health care providers, who must consider factors such as individual patient response, adverse effect profiles, drug interactions, and the potential need for escalation therapy, to optimize seizure control and overall patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some treatment challenges associated with Dravet syndrome? (
Strzelczyk, 2022 )- Please describe the different considerations HCPs must take into account when monitoring Dravet syndrome treatment to ensure optimal utilization of escalation therapy options.
Advertisement
Related to this article
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
2
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
3
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
4
Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype
5